Year: 2023
Type: article
Abstract: Even though genomics plays a critical role in the development of precision treatments for cancer, the actual treatments overwhelmingly target proteins, which are responsible for most cellular function.1 Moreover, from genomic sequencing alone, it is not possible to predict how translation is regulated, the rate of degradation of proteins, and post-translational modifications (PTMs) that are often independently regulated.Therefore, genomics alone cannot provide comprehensive information for precision treatment.Consequently, the integration of proteomics, transcriptomics and genomics in the field of proteogenomics holds the potential to unveil novel mechanisms and therapeutic targets. 2 Along this path, the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) has carried out proteogenomic characterization for over 10 cancer types.3 Many regulatory mechanisms and new therapeutic opportunities were revealed by integrated multi-omics analysis.
DOI: 10.1002/ctm2.1477
Language: English
Subfield: Spectroscopy
Field: Chemistry
Domain: Physical Sciences
Open Access status: gold
Estimated APC paid: $3,300
OpenAlex ID: W4389038211